stoxline Quote Chart Rank Option Currency Glossary
  
Vaxcyte, Inc. (PCVX)
82.44  2.88 (3.62%)    07-19 13:49
Open: 80.42
High: 82.44
Volume: 459,569
  
Pre. Close: 79.56
Low: 79.37
Market Cap: 8,969(M)
Technical analysis
2024-07-19 1:22:09 PM
Short term     
Mid term     
Targets 6-month :  99.99 1-year :  116.79
Resists First :  85.61 Second :  99.99
Pivot price 79.9
Supports First :  76.44 Second :  70.78
MAs MA(5) :  82.07 MA(20) :  78.87
MA(100) :  70.36 MA(250) :  61.38
MACD MACD :  2.5 Signal :  2.5
%K %D K(14,3) :  60.5 D(3) :  69
RSI RSI(14): 61.5
52-week High :  85.61 Low :  44.2
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PCVX ] has closed below upper band by 30.3%. Bollinger Bands are 17% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 84.15 - 84.65 84.65 - 85.03
Low: 78 - 78.64 78.64 - 79.12
Close: 78.71 - 79.67 79.67 - 80.37
Company Description

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Headline News

Thu, 18 Jul 2024
Swiss National Bank Boosts Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat

Thu, 18 Jul 2024
Swiss National Bank Has $12.16 Million Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX) - Defense World

Thu, 18 Jul 2024
Vaxcyte, Inc. (NASDAQ:PCVX) SVP Elvia Cowan Sells 5,000 Shares - American Banking and Market News

Wed, 17 Jul 2024
Elvia Cowan Sells 5,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock - MarketBeat

Thu, 11 Jul 2024
Elvia Cowan Sells 5,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock - American Banking and Market News

Tue, 02 Jul 2024
Vaxcyte Appoints John Furey to Board of Directors - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 109 (M)
Shares Float 99 (M)
Held by Insiders 0.6 (%)
Held by Institutions 112.2 (%)
Shares Short 9,680 (K)
Shares Short P.Month 9,520 (K)
Stock Financials
EPS -4.29
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 18.23
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -20.7 %
Return on Equity (ttm) -29.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -4.67
Qtrly Earnings Growth 0 %
Operating Cash Flow -408 (M)
Levered Free Cash Flow -305 (M)
Stock Valuations
PE Ratio -19.13
PEG Ratio 0.5
Price to Book value 4.49
Price to Sales 0
Price to Cash Flow -21.87
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android